Bibliografia UJ CM

1/9
Michael L. Wang, Wojciech Jurczak, Mats Jerkeman, Judith Trotman, Pier L. Zinzani, David Belada, Carola Boccomini, Ian W. Flinn, Pratyush Giri, Andre Goy, Paul A. Hamlin, Olivier Hermine, José-Ángel Hernández-Riva, Xiaonan Hong, Seok Jin Kim, David Lewis, F.R.C. Path, Yuko Mishima, Muhit Özcan, Guilherme F. Perini, Christopher Pocock, Yuqin Song, Stephen E. Spurgeon, John M. Storring, Jan Walewski, Jun Zhu, Rui Qin, Todd Henninger, Sanjay Deshpande, Angela Howes, Steven Le Gouill, Martin Dreyling.
Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma
New England Journal of Medicine
2022 : Vol. 386, nr 26, s. 2482-2494, il., bibliogr. 24 poz., abstr.
Autor korespondencyjny: Michael L. Wang.
p-ISSN: 0028-4793
e-ISSN: 1533-4406
AZ
ORG
AIF
IF: 158.500
Adres url:
Streszczenie w PubMed:
2/9
Michael Wang, Simon Rule, Pier Luigi Zinzani, Andre Goy, Olivier Casasnova, Stephen D. Smith, Gandhi Damaj, Jeanette K. Doorduijn, Thierry Lamy, Franck Morschhauser, Carlos Panizo, Bijal Shah, Andrew Davies, Richard Eek, Jehan Dupuis, Eric Jacobsen, Arnon P. Kater, Steven Le Gouill, Lucie Oberic, Tadeusz Robak, Preetesh Jain, Melanie M. Frigault, Raquel Izumi, Dorothy Nguyen, Priti Patel, Ming Yin, Monika Długosz-Danecka.
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
Leukemia
2019 : Vol. 33, nr 11, s. 2762-2766, bibliogr. 6 poz.
Autor korespondencyjny: Michael Wang.
Open Access Creative Commons Attribution License CC-BY 4.0.
p-ISSN: 0887-6924
LR
AIF
IF: 8.665
Adres url:
Streszczenie w PubMed:
3/9
Michael Wang, Simon Rule, Pier Luigi Zinzani, Andre Goy, Olivier Casasnovas, Stephen D. Smith, Gandhi Damaj, Jeanette Doorduijn, Thierry Lamy, Franck Morschhauser, Carlos Panizo, Bijal Shah, Andrew Davies, Richard Eek, Jehan Dupuis, Eric Jacobsen, Arnon P. Kater, Steven Le Gouill, Lucie Oberic, Taduesz Robak, Todd Covey, Richa Dua, Ahmed Hamdy, Xin Huang, Raquel Izumi, Priti Patel, Wayne Rothbaum, J. Greg Slatter, Wojciech Jurczak.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Lancet
2018 : Vol. 391, nr 10121, s. 659-667, il., bibliogr. 24 poz., sum.
Autor korespondencyjny: Michael Wang.
p-ISSN: 0140-6736
AZ
ORG
AIF
IF: 59.102
Adres url:
Streszczenie w PubMed:
4/9
Asher Chanan-Khan, Paula Cramer, Fatih Demirkan, Graeme Fraser, Rodrigo Santucci Silva, Sebastian Grosicki, Aleksander Pristupa, Ann Janssens, Jiri Mayer, Nancy L. Bartlett, Marie-Sarah Dilhuydy, Halyna Pylypenko, Javier Loscertales, Abraham Avigdor, Simon Rule, Diego Villa, Olga Samoilova, Panagiots Panagiotidis, Andre Goy, Anthony Mato, Miguel A. Pavlovsky, Claes Karlsson, Michelle Mahler, Mariya Salman, Steven Sun, Charles Phelps, Sriram Balasubramanian, Angela Howes, Michael Hallek, HELIOS investigators.
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Lancet. Oncology
2016 : Vol. 17, nr 2, s. 200-211, il., bibliogr. 22 poz., sum.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 33.900
Adres url:
5/9
Peter Martin, Kami Maddocks, John P. Leonard, Jia Ruan, Andre Goy, Nina Wagner-Johnston, Simon Rule, Ranjana Advani, David Iberri, Tycel Phillips, Stephen Spurgeon, Eliana Kozin, Katherine Noto, Zhengming Chen, Wojciech Jurczak, Rebecca Auer, Ewa Chmielowska, Stephan Stilgenbauer, Johannes Bloehdorn, Craig Portell, Michael E. Williams, Martin Dreyling, Paul M. Barr, Selina Chen-Kiang, Maurizio DiLiberto, Richard R. Furman, Kristie A. Blum.
Postibrutinib outcomes in patients with mantle cell lymphoma.
Blood
2016 : Vol. 127, nr 12, s. 1559-1563, il., bibliogr. 14 poz., abstr.
p-ISSN: 0006-4971
AZ
ORG
AIF
IF: 13.164
Adres url:
Streszczenie w PubMed:
6/9
Wojciech Jurczak, Pier Luigi Zinzani, Gianluca Gaidano, Andre Goy, Mariano Provencio, Zsolt Nagy, Tadeusz Robak, Kami J. Maddocks, Christian Buske, Sumeet Ambarkhane, Mark Winderlich, Maren Dirnberger-Hertweck, Jan Endell, Kristie A. Blum.
Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study.
Blood
2016 : Vol. 128, nr 22, s. 623
58th ASH Annual Meeting & Exposition, San Diego, California, 3-5 December 2016.
p-ISSN: 0006-4971
SZZ
SIF
Adres url:
7/9
Michael L. Wang, Kristie A. Blum, Peter Martin, Andre Goy, Rebecca Auer, Brad S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge E. Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, Peter Johnson, Stephen E. Spurgeon, Liang Zhang, Linda Baher, Mei Cheng, Dana Lee, Darrin M. Beaupre, Simon Rule.
Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results.
Blood
2015 : Vol. 126, nr 6, s. 739-745, il., bibliogr. 14 poz., abstr.
p-ISSN: 0006-4971
AZ
ORG
AIF
IF: 11.847
Adres url:
Streszczenie w PubMed:
8/9
Wojciech Jurczak, Simon Rule, Peter Martin, Rebecca Auer, Brad S. Kahl, Agnieszka Giza, Bożena Jachimczak, Ranjana H. Advani, Jorge Romaguera, Michael Williams, Jacqueline Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Jesse McGreivy, Fong Clow, Darrin M. Beaupre, Lori Kunkel, Andre Goy, Kristie A. Blum, Wiktor Jędrzejczak, Michael L. Wang.
Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórek płaszcza - wyniki międzynarodowego, wieloośrodkowego, badania II fazy z ibrutynibem (PCI-32765) - EHA Encore.
(Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma - Results of an International, Multicenter, Phase 2 Study of Ibrutinib (PCI-32765) - EHA Encore.)
Acta Haematologica Polonica
2013 : Vol. 44, nr 3, s. 314-318, il., bibliogr. 7 poz., abstr.
p-ISSN: 0001-5814
AP
ORG
KBN
Adres url:
DOI:
9/9
Michael L. Wang, Simon Rule, Peter Martin, Andre Goy, Rebecca Auer, Bras S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge E. Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, Peter Johnson, Stephen E. Spurgeon, Lei Li, Liang Zhang, Kate Newberry, Zhishuo Ou, Nancy Cheng, Bingliang Fang, Jesse McGreivy, Fong Clow, Joseph J. Buggy, Betty Y. Chang, Darrin M. Beaupre, Lori A. Kunkel, Kristie A. Blum.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
New England Journal of Medicine
2013 : Vol. 369, nr 6, s. 507-516, il., bibliogr. 29 poz., abstr.
p-ISSN: 0028-4793
AZ
ORG
AIF
IF: 54.420
Adres url:
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ